Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-12

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to develop the safety, feasibility, and tolerability of a personalized transcranial alternating current stimulation (tACS) approach in antenatal depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy: A Pilot Study

NCT02116127

Depression Pregnancy

COMPLETED NA

Transcranial Alternating Current Stimulation for Major Depressive Disorder

NCT02339285

Major Depressive Disorder MDD

COMPLETED NA

tDCS in Depression in Perinatal Women

NCT06015425

Depression Pregnancy

NOT_YET_RECRUITING NA

Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression

NCT05693922

Major Depressive Disorder

COMPLETED NA

Bipolar Transcranial Alternating Current Stimulation (tACS)

NCT05480124

Bipolar Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is an initial pilot study to develop the safety, feasibility, and tolerability of a novel, individualized transcranial alternating current stimulation (tACS) approach in antenatal depression, which delivers personalized stimulation waveforms based on the aperiodic component of individual participant EEG activity (PandA-tACS). In Phase I, five healthy controls will receive five consecutive days of PandA-tACS. High-density electroencephalography will be collected at Baseline, D1 and D5, as well as intermittently throughout stimulation sessions. Symptoms will be checked at FUP1 (two weeks following intervention). In Phase II, PandA-tACS will be expanded into five patients with antenatal depression with the same study design. In addition to HD-EEG measurements, depression and related symptoms will be measured at D1, D5 in these patients. Depression and related symptoms will be measured again FUP1 (two weeks following intervention) and FUP2 (4-6 weeks post delivery). Birth outcomes will be recorded within 90 days of expected delivery date as an additional form of safety monitoring.

Primary Aim: To investigate the safety, feasibility, and tolerability of five days of PandA-tACS in healthy controls (Phase I) and in participants with antenatal depression (Phase II).

Exploratory Aim: To investigate aperiodic EEG changes following five days of PandA-tACS in healthy controls and in participants with antenatal depression. Additionally, changes in depression symptoms will be investigated two weeks following PandA-tACS in antenatal depression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antenatal Depression Major Depressive Disorder Major Depressive Disorder in Pregnancy Healthy Controls

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

First phase of study involves healthy controls. Second phase of study involves patients with antenatal depression.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Control Group

Aperiodic tACS delivered using a waveform based on individual participant EEG activity which has been modified to alter excitation/inhibition balance.

Group Type EXPERIMENTAL

tACS (aperiodic)

Intervention Type DEVICE

Individualized tACS waveform based on aperiodic EEG activity will be delivered.

Antenatal Depression Group

Aperiodic tACS delivered using a waveform based on individual participant EEG activity which has been modified to alter excitation/inhibition balance.

Group Type EXPERIMENTAL

tACS (aperiodic)

Intervention Type DEVICE

Individualized tACS waveform based on aperiodic EEG activity will be delivered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tACS (aperiodic)

Individualized tACS waveform based on aperiodic EEG activity will be delivered.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

* Female aged 18 - 45
* Capacity to understand all relevant risks and potential benefits of the study as determined by study staff (provision of informed consent)
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Low suicide risk (defined for this study as no active suicidal ideation in the past month and no suicide attempts, preparatory actions, or significant non-suicidal self-harm in the previous 2 years). Risk will be assessed utilizing the C-SSRS screen and triage version with further exploration of positive responses.

For healthy control population:

* Use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation, according to NIH Therapeutics Research Program Guidelines.

Additional for antenatal depression population:

* Between weeks 14-32 of viable singleton pregnancy
* Established obstetric care through UNC
* Pre-identified DSM-5 diagnosis of unipolar, non-psychotic MDD which is confirmed by the DIAMOND
* HDRS-17 score ≥14

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

* DSM-5 diagnosis of severe alcohol use disorder (AUD) within the last 12 months, as evidenced by the DIAMOND
* DSM-5 diagnosis of moderate to severe substance use disorder (excluding tobacco) within the last 12 months, as evidenced by the DIAMOND
* Lifetime history of bipolar disorder, as evidenced by DIAMOND
* Schizophrenia spectrum and other psychotic disorders, as evidenced by DIAMOND
* History of autism spectrum disorder
* Initiated any new psychotropic medication in the 6 weeks prior to screening or had a dose change in the preceding 6 weeks
* Initiated a new course of psychotherapy in the 6 weeks preceding screening
* Received any neurostimulation treatment in the 6 weeks preceding screening
* History of seizures (excluding febrile seizures in childhood or Electroconvulsive Therapy (ECT) induced seizures)
* Neurological disorders that would increase risk of participation or present a significant confounder in the opinion of the investigator (for example, dementia, history of stroke, Parkinson's disease, multiple sclerosis, history of traumatic brain injury with prolonged loss of consciousness, ruptured cerebral aneurysm, previous CNS radiation)
* Previously failed to respond to ECT or transcranial magnetic stimulation (TMS)
* Prior brain surgery and/or brain implants
* Implanted medical device that uses electricity
* Currently enrolled in another clinical trial for depression
* Unstable medical disorder or anything that would place the participant at increased risk or preclude the participant's full compliance with or completion of the study, in the opinion of the Investigator

Additional for the healthy control population:

* Current pregnancy or lactation (as determined by urine pregnancy test)
* History of depression, as evidenced by DIAMOND

Additional for the antenatal depression population:

* History of any of the following conditions:

* Diabetes (gestational or general history)
* Pre-term delivery (\<37 weeks)
* Eclampsia
* Pre-eclampsia with severe features
* Asthma requiring daily medication
* Chronic hypertension
* Immune thrombocytopenia (ITP)
* Hyperthyroidism requiring medication
* Pre-pregnancy BMI 40 or more
* In vitro fertilization (IVF)
* Mullerian anomaly of uterus
* Organ transplant
* Prior history of deep vein thrombosis/pulmonary embolism (DVT/PE) or plan for anticoagulation during pregnancy
* Fetus with autoimmune hydrops
* Abnormal placenta
* Current pregnancy:

* HIV/Hep B/Hep C with detectable viral loads
* Anemia \[Hemoglobin under 11.0\] upon entry to prenatal care
* No scheduled prenatal visits by 15 weeks
* Placenta previa
* Placenta accreta spectrum (PAS)
* Pre-eclampsia
* Gestational diabetes
* Gestational hypertension
* Fetus with abnormal chromosomes
* Cervical length \< 2.5 cm
* Presence of cerclage or vaginal progesterone to decrease chance of pre-term labor
* Fetal growth restriction
* Macrosomia
* Polyhydramnios
* Oligohydramnios
* Rupture of membranes
* Hyperemesis Gravidarum (HEG)
* Confirmation testing for Tri 13/18/21
* Congenital anomalies on anatomy ultrasound that do not resolve with follow-up ultrasound
* Other cause of markedly high-risk pregnancy as determined by the Investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes